This article is more than 5 years old. Information may no longer be current.

Aperion Biologics appoints new members to its board of directors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aperion Biologics Inc. recently announced France Dixon Helfer and Mike Ward were appointed to the company’s board of directors.

Helfer currently serves as president and chief executive officer (CEO) of Halo Healthcare Inc. and was most recently the founder and CEO of Pegasus Biologics. Ward has more than 20 years of life sciences-dedicated investment banking, venture capital and private equity experience.  He currently serves on the boards of Nanosphere Inc. and CytoPherx Inc.

“France and Mike bring a wealth of experience, from private equity, venture capital, entrepreneurship, product development and business development,” Daniel Lee, CEO of the Aperion Biologics, stated in a company press release. “Their extraordinary industry experience will be a huge asset to the company as we move forward with our Z-Lig device, the first non-human biologic device for ACL reconstruction of the knee.”